Webinar 1:
Thursday, Feb. 19, 2009 Are Biomarkers the New Requirement for Dealmaking?
Big Pharma and Big Biotech companies say they will not collaborate on the development of new drugs unless the dossier contains biomarker data — biochemical evidence that a compound is hitting and modulating its target. Top business development executives talk about how biomarkers are driving value in today’s dealmaking environment.
